Adult High-Grade (Diffuse) Glioma

[1]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[2]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[3]  T. Mikkelsen,et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Weller,et al.  Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. , 2013, Neuro-oncology.

[5]  M. Mehta,et al.  RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. , 2013, International journal of radiation oncology, biology, physics.

[6]  J. Uhm,et al.  Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial , 2013, Clinical Cancer Research.

[7]  Spain,et al.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. , 2013, Neuro-oncology.

[8]  Susan M. Chang,et al.  Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. , 2012, Neuro-oncology.

[9]  H. Fine,et al.  A phase I/II trial of vandetanib for patients with recurrent malignant glioma. , 2012, Neuro-oncology.

[10]  R. Stupp,et al.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. , 2012, Neuro-oncology.

[11]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[12]  K. Aldape,et al.  Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas , 2012, Current Treatment Options in Oncology.

[13]  Daohai Yu,et al.  A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma , 2012, Journal of Neuro-Oncology.

[14]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[15]  C. Hartmann,et al.  CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas , 2012, Acta Neuropathologica.

[16]  C. Sander,et al.  Integrative Subtype Discovery in Glioblastoma Using iCluster , 2012, PloS one.

[17]  R. McLendon,et al.  Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma , 2012, Journal of Neuro-Oncology.

[18]  K. Ichimura.  Molecular pathogenesis of IDH mutations in gliomas , 2012, Brain Tumor Pathology.

[19]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[20]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[21]  P. Cassoni,et al.  MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors , 2012, Journal of Neuro-Oncology.

[22]  S. Leenstra,et al.  Recent advances in the molecular understanding of glioblastoma , 2009 .

[23]  Wei Wu,et al.  Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers , 2012, The Journal of pathology.

[24]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[25]  Pieter Wesseling,et al.  A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951 , 2011, Clinical Cancer Research.

[26]  Yuchen Jiao,et al.  Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011, Science.

[27]  Mitchel S Berger,et al.  An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.

[28]  Susan M. Chang,et al.  Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Neyns,et al.  Phase II study of sunitinib malate in patients with recurrent high-grade glioma , 2011, Journal of Neuro-Oncology.

[30]  K. Aldape,et al.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. , 2011, Neuro-oncology.

[31]  G. Ming,et al.  Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain , 2011, Cell.

[32]  P. Brastianos,et al.  Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis , 2011, Journal of Neuro-Oncology.

[33]  M. Delorenzi,et al.  Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial , 2011, Molecular Cancer Therapeutics.

[34]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[35]  Luis Souhami,et al.  Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison , 2011, Journal of Neuro-Oncology.

[36]  G. Reifenberger,et al.  Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010, Acta Neuropathologica.

[37]  O. Chinot,et al.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.

[38]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  W. Yung,et al.  Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. , 2010, Neuro-oncology.

[40]  Joel H. Saltz,et al.  The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas , 2010, PloS one.

[41]  P. Wen.  American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section , 2010, Expert review of anticancer therapy.

[42]  P. Wen,et al.  Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. , 2010, International journal of radiation oncology, biology, physics.

[43]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas , 2010, Targeted Oncology.

[44]  J. Hainsworth,et al.  Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first‐line treatment of patients with glioblastoma multiforme , 2010, Cancer.

[45]  Thomas Benner,et al.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Alessia Pica,et al.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[48]  D. Braddock,et al.  Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. , 2010, Biochemistry.

[49]  S. Kesari,et al.  Glioma stem cell signaling: therapeutic opportunities and challenges , 2010, Expert review of anticancer therapy.

[50]  Steven Piantadosi,et al.  Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States , 2010, Clinical Cancer Research.

[51]  W. Mason,et al.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[53]  Howard Colman,et al.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.

[54]  H. Fine,et al.  A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. , 2010, Neuro-oncology.

[55]  M. Weller,et al.  Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide , 2010, Journal of Neuro-Oncology.

[56]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[57]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. J. van den Bent,et al.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  L. Deangelis.  Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[61]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[62]  M. Nikiforova,et al.  Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.

[63]  P. Kleihues,et al.  Genetic alterations and signaling pathways in the evolution of gliomas , 2009, Cancer science.

[64]  M. J. van den Bent,et al.  Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma , 2009, British Journal of Cancer.

[65]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[66]  P. Wen,et al.  Antiangiogenic therapies for high-grade glioma , 2009, Nature Reviews Neurology.

[67]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  B. Neyns,et al.  Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[71]  A. Kaye,et al.  The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.

[72]  Robert G. Selker,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma , 2009 .

[73]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[74]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[75]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[76]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Yuri Kotliarov,et al.  Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. , 2009, Cancer research.

[78]  P. Mischel,et al.  A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) , 2009, Journal of Neuro-Oncology.

[79]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  K Skullerud,et al.  Can morphology predict 1p/19q loss in oligodendroglial tumours? , 2008, Histopathology.

[83]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[84]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[85]  S. Kesari,et al.  Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas , 2008, Nature Clinical Practice Oncology.

[86]  Jean-Yves Delattre,et al.  Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile , 2008, Molecular Cancer.

[87]  Timothy F Cloughesy,et al.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.

[88]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[89]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[91]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[92]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[93]  M Kiessling,et al.  Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma , 2007, International journal of cancer.

[94]  H Duffau,et al.  Temozolomide for low-grade gliomas , 2007, Neurology.

[95]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[96]  I. Shih,et al.  Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy: Figure 1. , 2007 .

[97]  Arie Perry,et al.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.

[98]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[99]  S. Franceschi,et al.  Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma , 2006, Journal of neuropathology and experimental neurology.

[100]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[101]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Susan M. Chang,et al.  Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 , 2005, Clinical Cancer Research.

[104]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[106]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[107]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[108]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[109]  M. Wolter,et al.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors , 2005, International journal of cancer.

[110]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[111]  K. Aldape,et al.  Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma , 2004, Cancer.

[112]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[113]  K. Makino,et al.  The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. , 2004, Journal of neurosurgery.

[114]  E. Bernhard,et al.  Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin , 2004, Oncogene.

[115]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[116]  Jan C Buckner,et al.  Factors influencing survival in high-grade gliomas. , 2003, Seminars in oncology.

[117]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[118]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[119]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[120]  W. Yung,et al.  Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis , 2003, Annals of neurology.

[121]  Guido Reifenberger,et al.  Pten signaling in gliomas. , 2002, Neuro-oncology.

[122]  K. Hoang-Xuan,et al.  Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression , 2001, Neurology.

[123]  K. Hoang-Xuan,et al.  Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study , 2001, Journal of neuropathology and experimental neurology.

[124]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[125]  D. Louis,et al.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. , 2001, The American journal of pathology.

[126]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[127]  M. member.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .

[128]  W. Curran,et al.  Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. , 2000, International journal of radiation oncology, biology, physics.

[129]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[130]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[132]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[133]  B. Scheithauer,et al.  Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. , 1998, Journal of neurosurgery.

[134]  Y. Yonekawa,et al.  PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas , 1998, Journal of neuropathology and experimental neurology.

[135]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[136]  C. James,et al.  PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. , 1997, Cancer research.

[137]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[138]  J R Feramisco,et al.  Enhanced Tumorigenic Behavior of Glioblastoma Cells Expressing a Truncated Epidermal Growth Factor Receptor Is Mediated through the Ras-Shc-Grb2 Pathway* , 1996, The Journal of Biological Chemistry.

[139]  D. Nelson,et al.  Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02 , 1996, Cancer.

[140]  W. Cavenee,et al.  Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. , 1995, Cancer research.

[141]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[142]  R. McLendon,et al.  Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. , 1995, Oncogene.

[143]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[144]  D. Levens,et al.  A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. , 1994, Genes & development.

[145]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[146]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[147]  G. Fuller,et al.  Amplified cellular oncogenes in neoplasms of the human central nervous system. , 1992, Mutation research.

[148]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[149]  J. Moossy,et al.  Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis , 1992, Journal of neuropathology and experimental neurology.

[150]  N. Bleehen,et al.  A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.

[151]  S B Green,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.

[152]  E. Alexander,et al.  Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. , 1989, International journal of radiation oncology, biology, physics.

[153]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[154]  R. Hatlevoll,et al.  Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.

[155]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[156]  M. Walker,et al.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.

[157]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[158]  H. Fine,et al.  Continuous daily sunitinib for recurrent glioblastoma , 2012, Journal of Neuro-Oncology.

[159]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[160]  Susan M. Chang,et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.

[161]  R. McLendon,et al.  Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma , 2010, Journal of Neuro-Oncology.

[162]  Suzanne Kamel-Reid,et al.  A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation , 2009, Cancer Chemotherapy and Pharmacology.

[163]  M. Aghili,et al.  Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review , 2008, Journal of Neuro-Oncology.

[164]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[165]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  P. Kleihues,et al.  Genetic alterations associated with the evolution and progression of astrocytic brain tumours , 2004, Virchows Archiv.

[167]  Stefano Colella,et al.  Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas , 2000, Laboratory Investigation.

[168]  W. Curran,et al.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.